Chongqing Xishan Science & Technology CO., Ltd. – Trademark Portfolio

Entity Type: 99

Chongqing Xishan Science & Technology CO., Ltd. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 5 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include XISHAN.

JUPITER SCIENCE & TECHNOLOGY DEVELOPMENT CENTER,

NO.9 HUANGSHAN RD. (MIDDLE), HIGH-TECH PARK, NEW NORTH ZONE 401121 CHONGQING

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Chongqing Xishan Science & Technology CO., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (5 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Chongqing Xishan Science & Technology CO., Ltd. have?

Chongqing Xishan Science & Technology CO., Ltd. has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Chongqing Xishan Science & Technology CO., Ltd. file in?

Chongqing Xishan Science & Technology CO., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Chongqing Xishan Science & Technology CO., Ltd.'s most well-known trademarks?

Chongqing Xishan Science & Technology CO., Ltd.'s registered trademark portfolio includes well-known marks such as XISHAN. These are among 3 currently registered trademarks in the portfolio.

What is Chongqing Xishan Science & Technology CO., Ltd.'s trademark registration success rate?

Chongqing Xishan Science & Technology CO., Ltd. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.